License therapeutic value
Agree product- and market-specific rights to therapeutic content and clinical evidence with manufacturers. Focus on markets they do not intend to enter themselves, with revenue sharing as the commercial model.
For investors
One platform. Multiple therapies. International growth.
DUX develops and operates digital therapeutics. We’re building on that foundation to bring clinically validated therapies into markets their creators don’t plan to enter themselves.
The opportunity
Clinical value can travel further.
A clinically validated digital therapy can have value beyond its original market. Entering another healthcare system takes local partnerships, regulatory work, integration into care and a viable route to revenue. For an individual manufacturer, that investment may sit outside its priorities.
DUX is building the platform and licensing model to open those markets. We bring together therapeutic content and clinical evidence from manufacturers with our software platform and local market partnerships. Our ambition is to make digital therapies available at health-system scale, including through public-sector partnerships.
The investment thesis: build the capability to bring multiple therapies into multiple markets on a shared technical and operational foundation. Each product and country still requires its own clinical, regulatory and commercial assessment.
How it works Reimplement applications on the mHealth Suite, adapting language, workflows and integrations to the intended use and local care setting. Shared modules and operating processes provide the foundation. Work with local partners to establish the route into care: the buyer, regulatory requirements, deployment, procurement and payment. Country opportunities become a business through executable agreements and local revenues.License. Implement. Bring into care.
Implement on our platform
Develop market access
The business model
An operating foundation. An international growth opportunity.
Development and operations: DUX builds and operates digital therapeutics for customers using the mHealth Suite. Setup fees and recurring operations fees underpin this business. Explore Build and Scale.
International licensing: we are developing manufacturer relationships and country partnerships for a revenue-share model. The next commercial milestones are product- and market-specific agreements, a contracted route into local care and initial local revenues. Explore Go Beyond.
Both activities draw on the same platform, development expertise and operating processes. Our aim is to reuse that foundation across a portfolio, so investment in the platform supports additional therapies and markets. International repeatability is the outcome we are building towards.
Why DUX The mHealth Suite provides modular infrastructure for digital therapeutics. DUX’s development and operations work gives the international model an existing technical foundation. Medical software requires controlled development, documentation, security and ongoing maintenance. Our quality management and certified development processes support this work. See certifications and their scope. DUX Healthcare grew out of fluidmobile, founded in Karlsruhe in 2012. Our experience spans mobile development and medical software, bringing implementation and operations into the same business. About DUX.Built on experience in medical software.
A shared technology foundation
Regulatory and operational experience
A team with continuity
Investor enquiries
An interest in the next chapter of digital health.
We are building relationships for a future VC round with investors who understand healthcare platforms, international market access and the path to recurring revenues.
Interested in the DUX investment case? Email us directly. Introductions through shared contacts are welcome.
Investor enquiries
Get in touch.
For investor enquiries and introductions: contact@dux-healthcare.com
. We share further business information in a personal exchange.
Email us